Successful treatment of the erythema and flushing of rosacea using a topically applied selective α1-adrenergic receptor agonist, oxymetazoline

Archives of Dermatology

Volumn 143, Issue 11, 2007, Pages 1369-1371

  Shanler, Stuart D ^b   Ondo, Andrew L ^a  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIBIOTIC AGENT; AZELAIC ACID; CLINDAMYCIN PHOSPHATE; METRONIDAZOLE; OXYMETAZOLINE; RETINOIC ACID; SULFACETAMIDE; SULFUR;

ADULT; AGED; ARTICLE; CASE REPORT; CLINICAL FEATURE; DIABETES MELLITUS; DISEASE EXACERBATION; DRUG SELECTIVITY; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; FLUSHING; HEART DISEASE; HUMAN; HYPERTENSION; MALE; PRIORITY JOURNAL; ROSACEA; SIDE EFFECT; SKIN BURNING SENSATION; SYMPTOMATOLOGY; TACHYPHYLAXIS; THYROID DISEASE; TREATMENT OUTCOME; TREATMENT RESPONSE; URINE RETENTION;

ADRENERGIC ALPHA-AGONISTS; AGED; ERYTHEMA; FEMALE; FLUSHING; HUMANS; MALE; MIDDLE AGED; OXYMETAZOLINE; PATIENT SATISFACTION; RECEPTORS, ADRENERGIC, ALPHA-1; ROSACEA; TELANGIECTASIS; TREATMENT OUTCOME;

EID: 36348992571     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.143.11.1369     Document Type: Article

References (18)

1. Crawford GH, Pelle MT, James WD. Rosacea, I: etiology, pathogenesis, and subtype classification. J Am Acad Dermatol. 2004;51(3):327-341.
2. Pelle MT, Crawford GH, James WD. Rosacea, II: therapy. J Am Acad Dermatol. 2004;51(4):499-512.
3. Wilkin J, Dahl M, Detmer M, et al. Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad Dermatol. 2002;46(4):584-587.
4. Plewig G, Kligman AM. Acne and Rosacea. 3rd ed. Berlin, Germany: Springer-Verlag; 2000:433-475.
5. Wilkin JK. Why is flushing limited to a mostly facial cutaneous distribution. J Am Acad Dermatol. 1988;19(2, pt 1):309-313.
6. Wilkin JK. Oral thermal-induced flushing in erythematotelangiectatic rosacea. J Invest Dermatol. 1981;76(1):15-18.
7. Parodi A, Guarrera M, Reboora A. Flushing in rosacea: an experimental approach. Arch Dermatol Res. 1980;269(3):269-273.
8. Ahlquist RP. A study of the adrenotropic receptors. Am J Physiol. 1948;153:586-600.
9. Kirstein SL, Insel PA. Autonomic nervous system pharmacogenomics: a progress report. Pharmacol Rev. 2004;56(1):31-52.
10. Piascik MT, Perez DM. Alpha1-adrenergic receptors: new insights and directions. J Pharmacol Exp Ther. 2001;298(2):403-410.
11. Civantos Calzada B, Aleixandre de Artinano A. Alpha-adrenoceptor subtypes. Pharmacol Res. 2001;44(3):195-208.
12. Guimarães S, Moura D. Vascular adrenoceptors: an update. Pharmacol Rev. 2001;53(2):319-356.
13. Hieble JP. Subclassification and nomenclature of alpha- and beta-adrenoceptors. Curr Top Med Chem. 2007;7(2):129-134.
14. Jarajapu YP, Johnston F, Berry C, et al. Functional characterization of alpha1-adrenoceptor subtypes in human subcutaneous resistance arteries. J Pharmacol Exp Ther. 2001;299(2):729-734.
15. Leech CJ, Faber JE. Different alpha-adrenoceptor subtypes mediate constriction of arterioles and venules. Am J Physiol. 1996;270(2, pt 2):H710-H722.
16. Bjerknes R, Steinsvag K. Inhibition of human neutrophil actin polymerization, phagocytosis, and oxidative burst by components of decongestive nose drops. Pharmacol Toxicol. 1993;73(1):41-45.
17. Beck-Speier I, Dayal N, Karg E, et al. Oxymetazoline inhibits proinflammatory reactions: effect on arachidonic acid-derived metabolite. J Pharmacol Exp Ther. 2006;316(2):843-851.
18. Chalothorn D, McCune DF, Edelmann SE, et al. Differences in the cellular localization and agonist-mediated internalization properties of the alpha(1)-adrenoceptor subtypes. Mol Pharmacol. 2002;61(5):1008-1016.